Polypeptide compounds
US5081107A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jun 6, 1989 |
| Grant date | Jan 14, 1992 |
| Priority date | — |
| Expiry date | Jun 6, 2009 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention releates to a polypeptide of formula I EQU R.sup.1 --CO--A.sup.1 --A.sup.2 --A.sup.3 A.sup.3 --A.sup.4 --A.sup.5 --A.sup.6 --Q wherein each of the generic terms is disclosed in full in the specification and includes PA1 R.sup.1 is a 5- or 6-membered unsaturated heterocyclic ring which contains one, two or three nitrogen atoms, which ring may optionally bear one or two substituents; a.sup.1 is a direct link to A.sup.2 ; or is His or D-His; A.sup.2 is Trp or MeTrp; A.sup.3 is Ala or MeAla; A.sup.4 is Val; A.sup.5 is Gly or D-Ala; A.sup.6 is His or Lys(Z); and Q is a group of the formula --A.sup.7.R.sup.2 in which A.sup.7 is Leu or LeMeu and R.sup.2 is hydroxy, amino, (1-3C)alkylamino or (1-3C)alkoxy; or Q is (1-6C)alkoxy or (1-10C)alkylamino. The compounds possess antagonist properties against bombesin-like peptides and are of value in treatment of malignant disease in warm-blooded animals.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.